WHAT'S KNOWN ON THIS SUBJECT: Individuals with DiGeorge syndrome (DGS) have varying degrees of immunodeficiency. All are susceptible to vaccine-preventable infections with serious complications. Although live vaccines are generally contraindicated in this population, limited evidence suggests that they may be effective and safe for select individuals.
DiGeorge syndrome (DGS) is most commonly caused by a chromosome 22q11.2 microdeletion that occurs in 1:3000 to 1:6000 births, making it one of the most prevalent chromosomal abnormalities affecting children. [1] [2] [3] [4] Thus, it is of particular public health importance. 5 Most patients with DGS have mild-to-moderate immunosuppression (ie, partial DGS); ∼1% have thymic aplasia with severe T-cell deficiency (ie, complete DGS) that may necessitate thymus or bone marrow transplantation. [6] [7] [8] [9] Patients with DGS are at increased risk of recurrent and/or prolonged viral infections, including vaccine-preventable infections (eg, varicella), 10, 11 and secondary bacterial infections. 7 Live vaccines are generally contraindicated in individuals with severe cellmediated immunodeficiency, such as complete DGS, yet may be considered in those with less-severe T-cell immunodeficiencies, such as partial DGS. 12, 13 Earlier small retrospective studies revealed that many patients with DGS received measlesmumps-rubella (MMR) and varicella vaccines. 10, 11 No serious adverse events (AEs) were reported after vaccination, although power was limited; 9% to 23% experienced minor AEs, comparable to rates seen in the general population. [13] [14] [15] Two small prospective studies similarly demonstrated that 7% to 21% of patients with DGS experienced minor AEs after MMR vaccination. 16, 17 Further characterization of vaccination patterns in this population, including differences in coverage and timeliness based on demographic characteristics, vaccine type (live versus inactivated), timing of diagnostic confirmation, and preceding immune function, is needed. A comprehensive investigation of live vaccine safety, including more recently introduced vaccines (ie, rotavirus), among patients with DGS is also warranted and may be enhanced using new causality assessment algorithms. [18] [19] [20] This study from the Clinical Immunization Safety Assessment (CISA) Network describes live vaccine-preventable illnesses, vaccination patterns, and adverse events following live immunization (AEFLIs) among 194 individuals with a documented chromosome 22q11.2 microdeletion.
METHODS
This retrospective cohort study was conducted by the CISA Network, a collaboration between the Centers for Disease Control and Prevention and select academic medical centers that conduct immunization safety assessments and research. 21 Individuals were eligible for inclusion if they had a chromosome 22q11.2 microdeletion detected by fluorescence in situ hybridization (FISH) assay, which was typically performed at initial diagnosis or to confirm a clinical diagnosis in those born before FISH assay became available (1993). 22 Subjects were identified by International Classification of Diseases, Ninth Revision searches, clinical data repository queries, and lists from subspecialists caring for patients with DGS. At 4 study sites, eligible individuals or their parents (if ,18 years old) gave informed consent and identified all providers from whom medical records were then requested. The fifth site received a waiver of informed consent for medical record abstraction. This study was approved by each site' s institutional review board.
Medical record abstractions were performed by trained study personnel by using standardized abstraction forms. Collected data included demographic characteristics (eg, gender,race/ethnicity), medical history (eg, FISH testing, cardiac history), laboratory studies (eg, all available lymphocyte subsets, lymphocyte proliferation responses to mitogens and specific antigens), immunization history,provider-documented live vaccinepreventable illnesses, and AEFLIs. Sites 1 and 3 (Table 1) abstracted AEFLI data from all 56-day postvaccination windows (eg, comprehensive approach).
For feasibility reasons, sites 2, 4, and 5 were limited to using a targeted approach, abstracting data only from the 56-day postvaccination windows identified by families during the enrollment process or providers during medical record ascertainment ("did [ Secondary outcomes included (1) live vaccine-preventable illnesses, defined as measles, mumps, rubella, varicella, or rotavirus illnesses based on history, examination, and/or laboratory confirmation (required of rotavirus infection); (2) vaccination coverage, described as MMR and varicella vaccination by 12 to 18 months and per the 4:3:1:3:3:1 schedule 23 for 19-to 35-month-olds with $1 health care encounter in the abstracted record after 18 months of age; and (3) vaccination timeliness, determined by age(s) at MMR and varicella vaccination (first dose) and diphtheria-tetanus-pertussis (whole-cell or acellular) (DTP/DTaP) vaccination (fourth dose). 24 Analyses of Haemophilus influenzae, hepatitis B, and varicella vaccinations included only children for whom these vaccines were available and recommended for similarly aged healthy children. 25 versus targeted), timing of FISH confirmation, hemodynamically significant cardiac disease, history of cardiac surgery, and CD4% before live vaccination or by age 12 to 18 months, if unvaccinated. Although all subjects had FISH confirmation at some time point, bivariate and multivariable analyses examining timing of FISH confirmation, dichotomized into early (,1 year of age) and late ($1 year of age), were limited to those born after this assay became available (1993) (n = 160). 22 CD4% were categorized as ,15% (severe immunosuppression), 15% to 24% (moderate immunosuppression), and $25% (no evidence of immunosuppression). 26 Lymphocyte proliferative responses to mitogens and specific antigens were categorized as normal (ie, positive, adequate) or abnormal (ie, low, decreased, negative).
Descriptive analyses were performed for demographics, timing of FISH confirmation,cardiac history,immunefunction, live vaccine-preventable illnesses, vaccination coverage, and AEFLIs. The causal relationships between live vaccination and rash or pneumonia, 2 commonly described complications of live vaccination in immunocompromised patients, [13] [14] [15] were assessed by using World Health Organization (WHO) criteria modified by CISA investigators 20 and a novel algorithm developed by the CISA Network. 18 If a subject died, cause of death provided in the medical record was accepted; previous live vaccine-preventable illnesses and vaccinations were reviewed.
The relationships between AEFLI and demographic characteristics, study site, abstraction procedure, timing of FISH confirmation, and cardiac history were assessed by using x 2 and Fisher' s exact tests. Similar analyses were performed for vaccination coverage. Factors found to be significant at P , .10 were added to the multivariable logistic regression models. CD4% results were compared between (1) live vaccinated and unvaccinated subjects and (2) subjects with and without AEFLIs using Wilcoxon-Mann-Whitney test. Timeliness of MMR, varicella, and DTP/DTaP vaccination was examined by using survival analyses. 27, 28 Individuals were censored when they received the vaccine of interest or at the time of last provider documentation in the abstracted record. Analyses were performed by using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS

Study Population
The study included 194 individuals born between 1974 and 2008 ( Table 1 ). The mean observation period was 8.3 years; subjects ranged in age between 0 and 31.5 years. All underwent FISH diagnostic confirmation, most (n = 120/194) before 1 year of age. Most (n = 121/194) had hemodynamically significant cardiac disease and underwent cardiac surgery. Many exhibited lymphocyte subsets below or in the low-normal range for healthy individuals (Supplemental Information Table 6 ). 29 One-third of subjects with available CD4% results (n = 41/121) had evidence of immunosuppression (CD4% ,25%); the proportion who were immunosuppressed did not differ based on timing of FISH confirmation. Among the 5% (n = 6/121) with documented severe immunosuppression (CD4% ,15%), total lymphocyte counts ranged from low (n = 1) to normal (n = 3), CD3/CD3% ranged from low (n = 4) to normal (n = 1), and CD8/CD8% ranged from low (n = 5) to normal (n = 1). 29 Most subjects with lymphocyte proliferation testing had normal mitogenic, but abnormal specific antigenic responses. Three of 25 subjects had an abnormal response to tetanus antigen: 1 previously unvaccinated, 1 vaccinated 20 years before testing, and 1 with booster vaccination ,1 month before testing; none had a CD4% ,25% around the time of testing. Five subjects died; no death was assessed to be related to live vaccination. No differences in timing of FISH confirmation, cardiac history, or immunosuppression were noted between study sites or based on abstraction procedure.
Live Vaccine-Preventable Illnesses
Fourteen subjects experienced a live vaccine-preventable illness (Table 2) . Of subjects unvaccinated against varicella (n = 59), 11 (19%) experienced varicella infection; none required ED visits or hospitalizations. Of subjects unvaccinated against rotavirus (n = 182), 3 (2%) were hospitalized with laboratory-confirmed rotavirus infection.
Vaccination Coverage and Timeliness
All subjects received at least 1 vaccine, 90% received at least 1 live vaccine, and 58% completed the 4:3:1:3:3:1 vaccination series by 19 to 35 months ( 
FIGURE 1
Live vaccination patterns according to timing of FISH diagnostic confirmation. Timeliness of MMR vaccination (gray) and varicella vaccination (black) between 0 and 36 months of age differed between those with FISH confirmation of a chromosome 22q11.2 microdeletion before 1 year of age (solid line) compared with those with FISH confirmation after 1 year of age (dashed line) (Kaplan Meier, P , .001).
Only 1 of 3 subjects with CD4% ,15% before live vaccination experienced an AEFLI (tonsillitis 1 month after MMR/ varicella vaccination). Mitogen testing was performed before MMR and varicella vaccination in 12 and 10 subjects, respectively. None had an AE after MMR vaccination. Three had minor AEs after varicella vaccination (eg, 1-114 and 1-191 in Table 5 ); only 1 of these had abnormal mitogen responses and evidence of immunosuppression (CD4% = 24%) between 2 and 6 years before vaccination.
DISCUSSION
Our study of 194 subjects with FISHconfirmed DGS is the largest to date describing live vaccine-preventable illnesses, vaccination patterns, and AEFLIs among patients with DGS. Contrary to American Academy of Pediatrics and Advisory Committee on Immunization Practices recommendations, 12,13 many received live vaccines despite having a confirmed chromosome 22q11.2 microdeletion and evidence of preceding immunosuppression. Although most had FISH confirmation before 1 year of age, only half had documented lymphocyte screening by 12 to 18 months and onethird of these had a CD4% ,25%. Of the latter, nearly 40% received MMR and/or varicella vaccines by 18 months of age. Nonetheless, AEFLIs were typically minor, as shown in smaller studies of subjects with DGS 10, 11, 16, 17 and the general population. [13] [14] [15] Few serious events were temporally associated with live vaccination, and none were assessed to be causally associated with live vaccination. These data are consistent with earlier studies 10, 11, 16, 17 and suggest that live vaccines may be given safely to some patients with DGS. The benefits of MMR and varicella vaccination, in particular, appear to outweigh the potential risks for patients with DGS with mild-tomoderate immunosuppression. Further investigation of MMRV vaccine, which may have a different safety profile than separate MMR and varicella vaccines, 31 and live vaccination of severely immunosuppressed patients with DGS is warranted given the small numbers included here.
The immune profile of our study population is consistent with mild-tomoderate immune deficiency and, thus, representative of the general DGS population (ie, partial DGS). [6] [7] [8] 32 Few unvaccinated individuals experienced severe live vaccine-preventable illnesses, as shown in a smaller cohort of patients with DGS with mild-to-moderate immunosuppression. 10 Another study reported higher rates of varicella illness among unvaccinated patients with DGS, which could reflect greater disease exposure, lower vaccine uptake, or less herd immunity. 11, 33 In our study, the paucity of severely immunosuppressed subjects could explain why there were relatively few AEFLIs despite high vaccination coverage. In support of this, patients with an AE after varicella vaccination had lower preceding CD4% (24.8%) versus those who did not (35.5%). These data, although limited, suggest that CD4 levels may be useful for predicting when live vaccines may be administered safely and could help guide provider vaccination decisions, as done in other immunocompromised populations. 12 Although no live vaccine-preventable illnesses and only 1 AEFLI (tonsillitis) were observed among the 6 subjects with severe immunosuppression (CD4% ,15%), additional retrospective data on this small subset of patients with DGS (estimated 1% nationally) are needed.
Overall, most subjects were up-to-date with inactivated vaccines and received them at appropriate ages. With respect to live vaccines, MMR vaccination coverage was high (77%), similar to that reported previously among patients with DGS (47%-88%), 10, 11 but lower than the ∼90% of US children aged 19 to 35 months who receive MMR vaccine. 10, 11, 23 Varicella vaccination coverage in our DGS cohort (75%) was higher than previously described (25%-54%), 10, 11 which may reflect lower varicella vaccine safety concerns among providers of our patients with DGS. Consistent with what has been shown in other high-risk populations, 28 our subjects exhibited no difference in timeliness of MMR, varicella, and DTP/DTaP vaccination overall. We did observe delayed live vaccination among those with early FISH confirmation (ie, ,1 year of age), many of whom may have had a more severe clinical presentation, as evidenced by a higher frequency of cardiac disease. After adjusting for cardiac disease, early FISH confirmation remained a negative predictor of MMR, but not varicella, vaccination. This could reflect MMR' s more limited licensing history and safety profile among immunocompromised patients compared with varicella vaccine [34] [35] [36] [37] [38] and lower measles versus varicella prevalence. 24 No difference in preceding CD4% was noted between vaccinated and unvaccinated subjects. This is consistent with existing data, 10 although potential withholding of varicella vaccine for more immunocompromised subjects has been described. 11 This study has some important limitations. It was a retrospective study of patients with complex health care needs and multiple providers. Medical management, including lymphocyte screening and vaccination practices, varied widely. The lack of CD4% data for many subjects may have resulted in an underestimation of immunosuppression.
Medical care received at multiple sites also made record collection challenging, although few incomplete records were identified through internal review and external queries. Different approaches for abstracting AEFLI data (ie, comprehensive versus targeted) likely explain the differential prevalence between sites, as no other site-based differences were detected. By introducing recall bias, the targeted approach may have resulted in fewer AEFLIs, especially minor ones, being detected. The lack of more serious AEFLIs at sites using the targeted approach also could be explained in part by the low incidence of such events. Although 69% of live vaccine doses were given at sites using the comprehensive approach, serious events at those sites were rare and not found to be causally associated with vaccination. Last, FISH testing was developed after some subjects were born, and age at the time of clinical DGS diagnosis was not available. For these individuals, the impact of diagnostic timing on vaccination decisions could not be assessed.
CONCLUSIONS
Our data expand the findings of smaller studies, 10, 11, 16, 17 indicating that live vaccination of patients with DGS with mild-to-moderate immunosuppression is well-tolerated. Prospective studies are needed to confirm our findings and offer guidance for live vaccination, as 
